Exploring the New Horizon of AdipoQ in Obesity-Related Alzheimer’s Dementia

Md. Sahab Uddin1,2*, Md. Motiar Rahman3, Mohammad Abu Sufian1,2, Philippe Jeandet4, Gulam Md. Ashraf5,6, May N. Bin-Jumah7, Shaker A. Mousa8, Mohamed M. Abdel-Daim9,10, Muhammad Furgan Akhtar11, Ammara Saleem12 and Md. Shah Amran13

1Department of Pharmacy, Southeast University, Dhaka, Bangladesh, 2Pharmakon Neuroscience Research Network, Dhaka, Bangladesh, 3Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS), Shenzhen, China, 4Research Unit, Induced Resistance and Plant Bioprotection, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences, University of Reims Champagne-Ardenne, Reims Cedex, France, 5Pre-clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia, 6Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia, 7Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, 8Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, New York, NY, United States, 9Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia, 10Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt, 11Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore, Pakistan, 12Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad, Pakistan, 13Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh

Alzheimer’s disease (AD) is the most common form of dementia, which causes abnormalities in learning, thinking, memory, as well as behavior. Generally, symptoms of AD develop gradually and aggravate over time, and consequently severely interfere with daily activities. Furthermore, obesity is one of the common risk factors for dementia. Dysregulation of adipokine and adipocyte dysfunction are assumed to be accountable for the high risk of obesity in people that develop many related disorders such as AD. Moreover, it has been observed that the dysfunction of adipose is connected with changes in brain metabolism, brain atrophy, cognitive decline, impaired mood, neuroinflammation, impaired insulin signaling, and neuronal dysfunction in people with obesity. Conversely, the pathological mechanisms, as well as the molecular players which are involved in this association, have been unclear until now. In this article, we discuss the impact of adiponectin (AdipoQ) on obesity-related Alzheimer’s dementia.

Keywords: Alzheimer’s disease, adipokine, AdipoQ, adipocyte dysfunction, obesity

INTRODUCTION

Alzheimer’s disease (AD) is the most frequent type of dementia among elderly individuals (Kabir et al., 2020a; Uddin et al., 2020d). It is characterized by the presence of two major hallmarks in the brain such as neurofibrillary tangles, predominantly formed by hyperphosphorylated tau proteins, and senile plaques, mainly composed of amyloid-beta (Aβ) peptides (Kabir et al., 2020b; Mamun et al., 2020). The latter hallmark is a major product of the proteolytic cleavage of the amyloid precursor protein (APP) by β- and γ-secretase
enzymes (Patterson et al., 2008; Uddin et al., 2020a). A major characteristic of AD is sporadic memory damages related to hippocampal affection. However, several pathological changes, such as oxidative stress, insulin resistance, neuroinflammation, or mitochondrial damage, are associated with obesity also result in AD pathological development (Najem et al., 2014; O’Brien et al., 2017; Ferreira et al., 2018; Uddin and Kabir, 2019).

Copious reports regarding the increase in body fat mass as well as the possibility of suffering from dementia have been published in the past few years (Whitmer et al., 2005; Businaro et al., 2012; Kivimäki et al., 2018). But, their outcomes are disputed and at several times inconclusive. It appears that it is significant to distinguish between being overweight at middle-age and in late-life (Xu et al., 2011), precisely, obesity in middle-aged life and reduction of bodyweight in the preclinical phase typify dementia (Singh-Maddineni et al., 2005). Indeed, in a meta-analysis of 21 trials, some authors have revealed that midlife obesity (i.e., <65 years) is associated with the development of dementia, but not after 65 years (Pedditizi et al., 2016). Another study investigated 1,349,857 individuals from 39 diverse cohorts with body mass index (BMI) data measured at baseline (Kivimäki et al., 2018). This study found that 20 years before dementia diagnosis, increased BMI was strongly related to a higher risk of dementia in mid-life. Analyses also demonstrated that this risk was inverted among late-life where an elevated BMI could even be a defensive factor against the risk of dementia (Kivimäki et al., 2018).

Adiponectin (AdipoQ) is a 30 KDa adipokine encoded by the AdipoQ gene, mostly produced by adipocytes and is rich in human plasma (Dendana et al., 2018). AdipoQ is recognized to enhance the insulin susceptibility of target organs including muscles and liver, finally controlling fatty acid metabolism and peripheral glucose levels (Hotta et al., 2001; Yamauchi et al., 2001, 2002). Also, being a metabolic controller, AdipoQ is additionally identified for its antioxidant and anti-inflammatory effects (Tanemura et al., 2007; Liu et al., 2015b). The central nervous system (CNS) is not relieved from the negative impact of obesity since obesity-related adipose malfunction has been connected to distorted neuroinflammation, brain metabolism, brain atrophy, neuronal dysfunction, cognitive decline, and impaired mood (Luppi et al., 2010; Gustafson, 2012; Arshad et al., 2018). People who suffer from obesity are under higher threat to disease progression in the case of age-linked cognitive failure, mild cognitive impairment (MCI), vascular dementia, and AD (Frisardi et al., 2010). Dysregulation of AdipoQ signaling may disrupt brain homeostasis and increase the risk of cognitive impairment. A better understanding of the impact of AdipoQ in AD is thus crucial. Particularly, restoring typical AdipoQ signaling might establish constructive, disease-modifying therapeutics against AD. Therefore, this article presents recent studies about AdipoQ on obesity-related AD.

**AdipoQ AND BRAIN TARGETS**

AdipoQ was primarily identified in 1995 in 3T3-L1 adipocyte differentiation (Scherer et al., 1995). It is considered as one of the most abundant adipokines taking into account its plasma levels compared to several other hormones (Matsuzawa, 2005; Thundyil et al., 2012; Polito et al., 2018). AdipoQ self-assembles into bigger shapes inducing homotrimer with epsilon self-assembly to construct hexamers or dodecamers. A globular AdipoQ resulting from the degradation of the monomer was additionally recognized (Waki et al., 2003). AdipoQ is largely produced and discharged from adipocytes, but, it is currently well-documented that these adipokines are produced by the liver, placenta, epithelial cells, pituitary cells, osteoblasts, and myocytes (Wilkinson et al., 2007; Psilopanagioti et al., 2009; Thundyil et al., 2012). Remarkably, various reports demonstrated AdipoQ mRNA expression in human pituitary (Psilopanagioti et al., 2009) and chicken diencephalon (Maddineni et al., 2005; Wilkinson et al., 2007). In the human pituitary, AdipoQ might have a role in the discharge of gonadotrophs and somatotrophs (Thundyil et al., 2012). Also, it controls a wide variety of metabolic actions such as the regulation of body-weight, lipid catabolism, glucose regulation, anti-atherogenic process, insulin sensitivity as well as endothelial function (Berg et al., 2002; Okamoto et al., 2002; Stefan and Stumvoll, 2002; Whitehead et al., 2006; Thundyil et al., 2012). Such activities are induced by three diverse receptors, namely T-cadherin (CDH13), AdipoQ receptor 1 (AdipoQR1), and AdipoQ receptor 2 (AdipoQR2), and involve various signaling cascades such as AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR)-α, c-Jun N-terminal kinases (JNK), and mitogen-activated protein kinases (p38-MAPK), and nuclear factor kappa B (NF-κB). These receptors look to be largely synthesized in the brain of various mammals including humans, mice, and rats, and their expression has been reported in distinct brain parts such as the hypothalamus, pituitary, and subcortical and cortical neurons (Degawa-Yamauchi et al., 2003; Yamauchi et al., 2003; Fry et al., 2006; Hoyda et al., 2007; Psilopanagioti et al., 2009; Thundyil et al., 2010, 2012).

Thundyil et al. (2012) studied the expression of AdipoQ receptors in the CNS and demonstrated that AdipoQR1 is mostly released in the brainstem, hypothalamus, and the pituitary gland whereas AdipoQR2 seems to be mainly released in the cortex. Moreover, AdipoQR1 is intensely released in neurons and a smaller amount in astrocytes since AdipoQR2 is believed to be weakly expressed in neurons and astrocytes (Thundyil et al., 2012). The AdipoQ gene is broadly expressed in the hippocampus and the cortex. On the other hand, the T-cadherin receptor (CDH13), which is one of the receptors mediating AdipoQ activity, seems to be spatially and temporally expressed in various neuronal cells during axon development (Ranscht and Dours-Zimmermann, 1991). Besides, T-cadherin exhibits wide expression in the brain hippocampus, cerebral cortex, amygdala, and basal ganglia in the postnatal telencephalon of Callithrix jacchus (Matsunaga et al., 2013). CDH13 was further expressed by projection neurons within the main as well as accessory olfactory bulbs. Remarkably, AdipoQ deficiency is
related to higher levels of inflammatory signals in serious illness or septic patients (Venkatesh et al., 2009; Hillenbrand et al., 2010, 2012). The expression of AdipoQR1 and AdipoQR2 was recently reported in primary human astrocytes and the U373 MG human glioblastoma astrocytoma cell line (Wan et al., 2014). It was further revealed that AdipoQ mediates pro-inflammatory signaling by rising interleukin (IL)-6, and monocyte chemoattractant protein 1 (MCP-1) notably via NF-κB, extracellular signal-regulated kinase (ERK)1/2, and p38-MAPK pathways in human astrocytes (Wan et al., 2014). Additionally, it has been suggested that AdipoQ may also regulate neuroinflammation by decreasing inflammatory cytokine expression through brain endothelial cells (Spranger et al., 2006).

A study reported the decreased expression of total AdipoQ and its high molecular weight oligomers in patients with common variable immunodeficiency (Pecoraro et al., 2017). A further study also revealed different expression patterns of AdipoQR1 and AdipoQR2 in the peripheral blood mononuclear cells of these patients (Polito et al., 2019).

AdipoQ IN COGNITIVE FUNCTION

Synapse dysfunction is the major pathological hallmark of cognitive impairment in AD (DeKosky and Scheff, 1990; Terry et al., 1991). Exciting data suggest that Aβ oligomers serve as neurotoxins that accumulate in the brain of AD patients leading to synaptic dysfunction and impaired synaptic plasticity as well as triggering synapse injury (Lambert et al., 1998; Ferreira and Klein, 2011; Forny-Germán et al., 2014). Oligomeric Aβ prevents long term potentiation (LTP) and thus stimulates long term depression (LTD) of hippocampal synapses both in vitro and in vivo (Wang et al., 2002; Shankar et al., 2008; Li et al., 2009; Jürgensen et al., 2011).

Several studies have proposed that AdipoQ signaling directly controls synaptic activity as well as plasticity, and maintaining and increasing cognitive activities in a variety of models. In anesthetized rats, intracerebroventricular administration of AdipoQ potentiates high-frequency stimulation (HFS)-mediated LTP and suppresses low-frequency stimulation (LFS)-mediated LTD (Pousti et al., 2018). Also, AdipoQ administration mediates a chemical LTP, irrespective of presynaptic incentive (Pousti et al., 2018). Treatment with a plant-derived homolog of AdipoQ (osmotin) modulated AdipoQ receptors ameliorated LTP damage and memory discrepancies in AD models (Shah et al., 2017). This activity seems to be induced by the Nogo66 receptor 1 and AdipoQ1R and comprises an outgrowth of neurite development and a rise of the dendritic spine as well as synapse density in the hippocampus (Shankar et al., 2008; Li et al., 2009; Jürgensen et al., 2011).

Adipoknockout mice show elevated excitability of the hippocampal dentate gyrus (DG) granule neurons together with reduced loss of contextual fear memory. AdipoQ and its analog drug Adipor1, reestablished fear memory loss through AdipoQR2 stimulation and prevention of the excitability of DG neurons (Zhang et al., 2016; Yoon et al., 2018).

AdipoQ-knockout mice show increased excitability of the hippocampal dentate gyrus (DG) granule neurons together with reduced loss of contextual fear memory. AdipoQ and its analog drug AdipoRon, reestablished fear memory loss through AdipoQR2 stimulation and prevention of the excitability of DG neurons (Zhang et al., 2017). Elderly AdipoQ-knockout mice display decreased concentrations of synaptic proteins proposing synapse impairment, and poor scores in contextual fear conditioning and spatial memory tests (Ng et al., 2016). Interestingly, both osmotin and AdipoQ treatments improve learning as well as memory insufficiencies in AD animal models (Ali et al., 2015; Shah et al., 2017). Caloric constraints enhance circulating AdipoQ concentrations and increase cognition in mice perhaps through controlling the AMPK pathway in the mouse hippocampus (Ma et al., 2018). Furthermore, a clinical trial reported that patients with elevated AdipoQ concentrations exert better performances in a prolonged word memory test, advocating the idea that AdipoQ is a protective factor against cognitive failure suggesting a novel therapeutic approach in cognitive decline (Cezaretto et al., 2018).

AdipoQ IN ALZHEIMER’S HALLMARKS

Animal Studies

Study suggests that insufficiency in AdipoQ signaling can mediate an AD-like symptom in mice models (Table 1; Ng et al., 2016). Aged AdipoQ-deficient mice recapitulate various features of AD pathology, such as increased levels of Aβ, synaptic loss, neuroinflammation, tau hyperphosphorylation, neuronal cell death, and reduced insulin signaling. Significantly, aged AdipoQ deficient mice accomplished poor activity upon fear conditioning behavioral experiments and spatial memory (Ng et al., 2016). This study also indicated that chronic deficiency of AdipoQ in aged mice inactivates AMPK signaling thus causing insulin desensitization and provokes AD-like cognitive impairments as shown in Figure 1. The above interpretations were again validated by another analysis showing that gene-therapy mediated AdipoQR1 suppression further induces AD-like pathogenesis, which comprises dysfunction in the spatial memory as well as learning, insulin signaling deficiency, elevated concentrations of Aβ accretions and hyperphosphorylated tau, neuroinflammation as well as other neurodegenerative events (Kim et al., 2017). These analyses afford convincing reports for the implication of AdipoQ deficiency in the pathogenesis of AD. The nucleus basalis magnocellularis (NBM) is a well-known cholinergic nucleus in the basal forebrain that is disturbed rigorously in AD along with other neurodegenerative disorders. It has been reported that the dysfunction of NBM cholinergic neurons influences cholinergic loss and, more notably, is associated with clinical events of dementia (Arendt et al., 1983; Iraiozz et al., 1999; Liu et al., 2015a). Fascinatingly, NBM was reported to be an eminent site of AdipoQR1 expression (Psipapanagioti et al., 2009). Hence, it is likely that a lack of AdipoQ stimulates the development of AD by stimulating NBM degeneration.

Conversely, loss in AdipoQ activity was also detected in amyloid-induced AD prototypes, while triggering the AdipoQ signaling pathway declines AD-like phenotypes. APP/PS1 mice displaying alterations in the levels of AdipoQ receptor expression seemed less reactive to a stress-mediating mice model as compared to control mice (Várheleyi et al., 2017). In an identical paradigm, osmotin improved AD-like phenotypes, for example, Aβ formation and deposition, synaptic loss and deficient LTP, and cognitive decline and memory loss. AdipoQR1 silencing eliminates the
TABLE 1 | Several promising studies of the role of AdipoQ signaling in physiopathological processes associated with Alzheimer’s disease.

| Therapeutic agent/target | Species/studied material/model(s) | Effects | Mechanism | References |
|--------------------------|---------------------------------|---------|-----------|------------|
| AdipoQ | AdipoQ-deficient (AdipoQ<sup>−/−</sup>) mice, AdipoQ-haploinsufficient (AdipoQ<sup>−/+</sup>) mice | Neurotrophic effects on dendritic spine remodeling and neurogenesis in the dentate gyrus | Neurotrophic effects of AdipoQ | Zhang et al., 2016 |
| Osmotin | AdipoQ<sup>−/−</sup> mice, B6.Cg-Tg (APPswe, PSEN1E9)55Dbo/ Mmax AD model mice, C57BL/6J-Tg (NSE-APPswe) KlAR mice | Enhances the non-amyloidogenic pathway by activating the α-secretase gene and reverses the suppression of long-term potentiation | Modulates AdipoQR1/AMPK (AMPK-activated protein kinase)/SIRT1 (Sirtuin 1)/SREBP2 (sterol regulatory element-binding protein 2) signaling pathway | Shah et al., 2017 |
| AdipoQ | Adult male Wistar rats | Modulates synaptic plasticity in the hippocampal dentate gyrus | Enhances the long-term potentiation and suppresses long-term depression | Pousti et al., 2018 |
| Osmotin | C57BL/6J-Tg (APPswe/ PSEN1E9) mice | Enhances neurite outgrowth and synaptic complexity | | Yoon et al., 2018 |
| AdipoQ | AdipoQ-deficient mice | AdipoQ deficiency causes AD-like synapse loss and memory impairment | AMPK inactivation and cerebral insulin resistance | Ng et al., 2016 |
| Osmotin | Male wild-type C57BL/6 J mice | Prevents Aβ<sub>42</sub>-induced apoptosis, neurotoxicity, tau phosphorylation, and neurodegeneration | Modulates AdipoQR (adiponectin receptor) | Ali et al., 2015 |
| AdipoQ | AdipoQR1<sup>−/−</sup> mice | AdipoQ deficiency leads to memory dysfunction and AD-like pathologies | Suppresses AdipoQR1 | Kim et al., 2017 |
| AdipoQ (enriched environment-mediated) | | | | |
| Globular AdipoQ | AdipoQ<sup>−/−</sup> mice, AdipoQR2<sup>−/−</sup> mice | Anti-inflammatory and anti-oxidant actions on microglia | Activates anti-inflammatory state | Chabry et al., 2015 |
| AdipoQ | 5xFAD male transgenic mice, wild-type male C57BL/6 mice | Promotes anti-inflammatory responses on microglia | Modulates AdipoQR1 (adiponectin receptor 1)/NF-κB (nuclear factor-κB) signaling Pathway | Nicolas et al., 2017 |
| Recombinant C1q/TNF-related protein 9 (CTRP9) | BV2 microglial cells exposed to Aβ | Attenuates neuroinflammation, reduces brain edema, and improves neurological function | Activates AdipoQR1/AMPK/NF-κB signaling | Zhao et al., 2018 |
| AdipoQ | Male Sprague-Dawley rats | Inhibits cerebral expression of myeloperoxidase and inflammatory mediators | Activates anti-inflammatory state and controlling NF-κB (p65) | Chen et al., 2009 |
| AdipoQ | Male ICR mice | Protects hippocampal neurons | Preservation of the integrity of the blood-brain barrier (BBB) | Jeon et al., 2009 |
| AdipoQ | Primary hippocampal cell cultures | Reduces the level of reactive oxygen species, attenuates apoptotic cell death, and also suppresses the caspase-3 activation | Modulates AMPK pathway | Qiu et al., 2011 |
| AdipoQ | SH-SY5Y cell line | Reduces Aβ neurotoxicity | Activates AMPK and suppresses the NF-κB activation | Chen et al., 2012 |
| Global AdipoQ | Male C57BL/6 mice | Promotes antioxidant capacity | Inhibits NADPH oxidase-mediated oxidative damage | Song et al., 2013 |
| Global AdipoQ | Adult male C57BL/6 mice | Improves neurological scores and reduces the infarct volumes | Modulates AdipoQ/AdipoQR expression | Song et al., 2015 |
| AdipoQ (electroacupuncture pretreatment) | Male C57BL/6 mice | Exerts neuroprotective effects | AdipoQR1-mediated phosphorylation of glycogen synthase kinase-3β (GSK-3β) | Guo et al., 2015 |
| CTRP3 | Adult male Sprague-Dawley rats | Attenuates brain injury | Modulates AMPK-dependent pathway | Wang et al., 2016 |
| CTRP3 | Male Sprague-Dawley rats | Reduces cerebral edema, oxidative stress, and BBB damage and improves neurological functions as well as brain antioxidant enzymes | Modulates NADPH pathway | Yang et al., 2017 |
| AdipoQ (caloric restriction-induced) | C57/BL mice | Improves hippocampus-dependent learning and memory | Modulates AMPK signaling pathway | Ma et al., 2018 |
| AdipoQ (physical exercise-induced) | Male WT C57BL/6 J mice, AdipoQ<sup>−/−</sup> mice | Promotes hippocampal neurogenesis and depression | Activates the ADNR1/AMPK signaling pathways | Yaua et al., 2014 |
| AdipoQR1 and AdipoQR2 | Male C57BL/6 J mice, APP<sub>swe</sub>/Presen<sub>e9d1</sub> (AD) mice | AdipoQRs are less sensitive to stress | Modulates AdipoQR expression | Vahrøy et al., 2017 |
beneficial effects of osmotin and additionally aggravates brain pathology in AD-mice (Shah et al., 2017). Osmotin was also found to diminish Aβ accumulation in the cultured cells of SH-SY5Y human neuroblastoma overexpressing APP. Osmotin actions are induced by stimulation of the AMP kinase, an enzyme downregulated by oligomeric Aβ in hippocampal neurons (Seixas da Silva et al., 2017). An intracerebroventricular dose of AdipoQ recovered cognitive decline and reduced glycogen synthase kinase 3β (GSK3β)-induced tau hyperphosphorylation in AD-related areas in a rat paradigm of streptozotocin-mediated brain pathology (Xu et al., 2018). These reports propose the stimulation of the AdipoQ signaling pathway, predominantly via AdipoQR1, as a novel therapeutic target in AD (Ng and Chan, 2017). Considering this, chronic administration of a widely used anti-AD acetylcholinesterase antagonist (i.e., donepezil) was found to elevate serum concentrations of AdipoQ (Pakaski et al., 2014). Furthermore, thiazolidinediones (TZDs) including pioglitazone, as well as PPARγ agonists (i.e., used for type 2 diabetes mellitus; Saltiel and Olefsky, 1996; Malinowski and Bolesa, 2000; Hong et al., 2018) were just repurposed to combat AD. The insulin-sensitizing function of TZDs is in part induced by triggering peripheral AdipoQ receptors and AdipoQ gene expression (Yu et al., 2002; Tsuchida et al., 2005; Nie and Li, 2017). Consequently, it is feasible that AdipoQ exerts part of the experimental benefits of TZDs and donepezil.

AdipoRon, an AdipoQ receptor agonist (Okada-Iwabu et al., 2013), has been shown to regulate hippocampal synaptic transmission and to accelerate fear memory loss in rodents (Zhang et al., 2017). Also, AdipoRon was shown to control dopaminergic neuronal activity in the ventral-tegmental site (Sun et al., 2019) and act as a metabolic and antidepressant controller in a mouse model of depression (Nicolas et al., 2018). Notably, central AdipoRon activities were achieved by peripheral inoculation, and it has been found that this drug passes the blood-brain barrier (BBB) to trigger AdipoQ receptors in the brain. It would be exciting to further examine the effects of this AdipoQ-drug analog with translational potential in AD models.

### Human Studies

In humans, analyses relating AdipoQ concentrations to AD are debatable. Improved baseline AdipoQ concentrations in plasma were found to be involved with an elevated risk of developing AD and other forms of dementia in women, but not men (Table 1; van Himbergen et al., 2012). Moreover, increased AdipoQ levels were revealed in the cerebrospinal fluid (CSF) and plasma of individuals with MCI as well as sporadic AD (Une et al., 2011; Khemka et al., 2014), while plasma concentrations of AdipoQ was positively associated with dementia. The relationship between AD and increased blood AdipoQ levels has been advocated by meta-analysis (Ma et al., 2016). Though the afore-mentioned reports suggest elevated AdipoQ concentrations to be related to Alzheimer’s dementia, conflicting effects have also been described. Data analysis has shown decreased concentrations of AdipoQ in MCI and AD individuals. Furthermore, based on the AdipoQ levels, one is

---

**TABLE 1 | Continued**

| Therapeutic agent/target | Species/studied material/model(s) | Effects | Mechanism | References |
|--------------------------|----------------------------------|---------|-----------|------------|
| AdipoQ supplements       | Streptozotocin injected male Sprague-Dawley rats | Reduces tau hyperphosphorylation and increases dendritic branches number and mushroom percentage | Activates the PI3K (phosphatidylinositol 3-kinase)/Akt (protein kinase B/GSK-3β) signaling pathway | Xu et al., 2018 |
| AdipoQ                   | Middle-aged-to-elderly community-dwelling persons | Deficiency of plasma AdipoQ was associated with mild cognitive impairment (MCI) in men | Neuroprotective effects of AdipoQ | Kamogawa et al., 2010 |
| AdipoQ                   | Non-diabetic participants of ELSA-Brasil | Enhances cognitive performance | - | Cezaretto et al., 2018 |
| AdipoQ                   | MCI and Alzheimer’s disease (AD) patients | Plasma AdipoQ was considerably higher in MCI and AD, while cerebrospinal fluid (CSF) AdipoQ was meaningfully higher in MCI compared to controls | - | Une et al., 2011 |
| AdipoQ                   | Women with a median age of 76 years (prospective cohort study) | Increased plasma AdipoQ levels serve as a risk factor (independent) for the progression of all-cause dementia and AD | - | Van Himbergen et al., 2012 |
| AdipoQ                   | MCI and AD patients | Deficiency of AdipoQ was linked to cognitive dysfunction (however additional cognitive decline/dementia was not predicted in this cohort) | - | Teixeira et al., 2013 |
| AdipoQ                   | Probable AD patients | Alteration of serum AdipoQ levels implies amyloid pathology, neurodegeneration, and hypometabolism of glucose | - | Khemka et al., 2014 |
| AdipoQ                   | Type 2 diabetes patients | AdipoQ deficiency correlates with AD-like brain changes | - | Garcia-Casares et al., 2016 |
| AdipoQ (Baduanjin Qigong exercise-induced) | Female participants with chronic fatigue syndrome-like illness | Reduces symptoms of depression | Modulates AdipoQ levels | Chan et al., 2017 |
not able to foresee the development of cognitive decline from normal conditions to MCI and from MCI to AD, respectively (Teixeira et al., 2013). Another report also revealed that reduced concentrations of AdipoQ in plasma were involved with MCI, although this link was identified in males, but not in females (Kamogawa et al., 2010). From these experiments, it has been found that decreased levels of plasma AdipoQ in diabetic patients is associated with a lower volume of gray-matter and lower glucose uptake in the temporal region of the brain, comparable to what is perceived in AD (García-Casares et al., 2016). Furthermore, another study reveals that AdipoQ concentrations in blood are elevated but the lower levels are reported in CSF of MCI and AD individuals. Existing studies concerning a link between AdipoQ concentrations in blood and CSF to MCI and AD are inconsistent and questionable. Hence, more analyses are needed to explore the precise impact of AdipoQ.

FIGURE 1 | The role of AdipoQ deficiency in the pathogenesis of Alzheimer’s disease through AMPK inactivation. In neurons, AdipoQ deficiency leads to decreased AMPK activation and increased phosphorylation of IRS-1 S616 that inhibits the pIRS-1 Y636/638 formation, and thus deactivates insulin signaling. On the other hand, insulin resistance is gradually developed and reduces pAkt S473 Levels. Thus, decreased Akt induction and increased GSK3β activation results in increased Aβ production and tau phosphorylation. Furthermore, insulin resistance exacerbates the extracellular Aβ deposition as well as impaired synaptic plasticity. AMPK, AMP-activated protein kinase; IRS, insulin receptor substrate; GSK3β, glycogen synthase kinase 3β; Akt, protein kinase B; Aβ, amyloid beta peptide.
been reported with females being at a considerably increased risk of developing AD than males (Uddin et al., 2020c).

**AdipoQ IN NEUROINFLAMMATORY SIGNALING OF ALZHEIMER’S DISEASE**

The brain of AD patients exerts a prolonged state of low-level inflammation, which is induced by the activation of microglial cells that leads to the secretion of several inflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor-α (TNFα), and IL-1β (Bamberger et al., 2003; Lourenco et al., 2013; Heneka et al., 2015; Hansen et al., 2018; Uddin et al., 2020b). These cytokines induce various harmful incidents in the AD brain such as endoplasmic reticulum stress, neuronal insulin resistance, synaptotoxicity, and finally neurodegeneration (Bomfim et al., 2012; Lourenco et al., 2013; Rizzo et al., 2018).

AdipoQ-deficient mice possess a variety of clinical features in the AD brain, such as decreased concentrations of synaptic proteins, insulin resistance, and the existence of neuroinflammatory markers including astrogliosis, microgliosis, and higher concentrations of the inflammatory cytokines such as IL-1β and TNFα (Ng et al., 2016). Environmental upgrading like housing situations that stimulate social interactions, cognitive engagement, and physical activity, has been found to increase cognitive activities in AD mice. These results are at least in part owing to the alteration of the microglial effect to the insults of neurotoxic Aβ oligomers (Xu et al., 2016; Vieira and Beckman, 2017). Recently, it has been shown that beneficial outcomes of environmental upgrading to the brain are induced by AdipoQ including the advancement of an anti-inflammatory state of microglia with the lower secretion of inflammatory cytokines (Chabry et al., 2015; Nicolas et al., 2015). It has also been reported that globular AdipoQ prevents the microglia inflammatory profile directly in vivo and in vitro (Nicolas et al., 2017) via a mechanism involving NF-κB and AdipoQR1. AdipoQ also regulates the in vitro activation of microglia under Aβ toxicity through PPARγ stimulation (Song et al., 2017). Another report suggesting the anti-inflammatory effects of AdipoQ in the CNS shows that an AdipoQR1 agonist (i.e., CTRP9) reduces neuroinflammatory effects in an in vivo mouse model of intracerebral hemorrhage via AdipoQR1/AMPK/NF-κB signaling pathways (Zhao et al., 2018). Besides, AdipoRon usage was found to block the recruitment of macrophages in an experimental model of spinal cord damage (Zhou et al., 2019).

AdipoQ was reported to prevent the pro-inflammatory response, remarkably by blocking IL-6 discharge from BBB endothelial cells (Spranger et al., 2006). It has been shown that AdipoQ regulates inflammatory signaling indirectly through the BBB by adversely modulating TNFα and IL-6 release. Laboratory analysis of hippocampal neurons has indicated that AdipoQ mediates neuroprotective effects via the AMPK signaling pathway (Qiu et al., 2011). Such effects are additionally supported by experiments demonstrating that AdipoQ knockout mice show enlarged brain injuries and increased neurological deficits after ischemia-reperfusion compared with wild-type mice (Nishimura et al., 2008). These studies provide evidence that the neuroprotective effect of AdipoQ is induced via an endothelial nitric oxide synthase (eNOS)-reliant mechanism (Nishimura et al., 2008). Thus the neuroprotective role of AdipoQ takes part in the regulation of brain inflammation; it was proposed that the lack of AdipoQ in obesity might induce neuroinflammation leading to AD and other dementias.

**AdipoQ IN INSULIN SIGNALING OF ALZHEIMER’S DISEASE**

Neuronal insulin signaling plays an important role in memory and synaptic plasticity, mostly by controlling glutamate receptor transport (Beattie et al., 2000; Man et al., 2000; Skeberdis et al., 2001; Zhao et al., 2004). Defective insulin signaling is well-reported both in AD individuals and in a number of AD animal models (Steen et al., 2005; Bomfim et al., 2012; Talbot et al., 2012). Impaired insulin signaling is responsible for the neuronal loss and cognitive decline in AD (Ferreira et al., 2014; Vieira et al., 2018). The synaptotoxicity of Aβ is associated with a loss of insulin receptor activity in vivo and in vitro and can be inhibited by using insulin itself and by insulin-sensitizing medications (De Felice et al., 2009; Bomfim et al., 2012; Batista et al., 2018). These findings prompted numerous groups to investigate the activity of various types of anti-diabetic therapies in AD prototypes, and progressive preclinical outcomes triggered researchers to complete human clinical tests (De Felice, 2013; Yarchao and Arnold, 2014; de la Monte, 2017). In this regard, attention has been focused on the insulin-sensitizing activities of AdipoQ to rectify the abnormal insulin signaling in AD.

A diminished brain insulin signaling cascade was detected, along with various other AD-resembling pathological symptoms, in AdipoQ-deficient mice as well as in AdipoQR1-knockout mice (Ng et al., 2016; Kim et al., 2017). In contrast, AdipoQ was found to enhance insulin susceptibility in the SH-SY5Y neuroblastoma cell line exhibiting insulin resistance, via AdipoQR1 initiation of AMPK (Ng et al., 2016). These studies reveal that AdipoQ possesses the possibility to reestablish neuronal insulin signaling, with potential therapeutic effects for AD and also other neurodegenerative disorders (Bloemer et al., 2018). Nevertheless, more translational analyses using AD models are needed to authenticate the neuroprotective role of AdipoQ as therapeutic interventions to halt brain insulin resistance in AD.

Other studies suggested that insulin resistance (Capurso and Capurso, 2012; Johnson and Olefsky, 2013; Medina-Urrutia et al., 2015) is associated with an excess of adiposity induced by high free fatty acid (Perseghin et al., 2003) and lower levels of plasma AdipoQ (Arita et al., 2012). Furthermore, acute lowering of free fatty acid is linked to decreased AdipoQ levels (Bernstein et al., 2004). A study has revealed that the altered plasma status of both docosahexaenoic acid and other fatty acids unrelated to docosahexaenoic acid are linked to AD (Cunnane et al., 2012).
AdipoQ PARADOX IN ALZHEIMER’S DISEASE

AdipoQ is a well-known neuroprotective agent against various cytotoxicities induced by Aβ as well as MPP⁺ in vitro (Jung et al., 2006; Chan et al., 2012). In mice brains, AdipoQ is protected from kainic acid-mediated excitotoxicity in the hippocampus (Jeon et al., 2009). Particularly, AdipoQ may control neurogenesis. Regarding this concept, AdipoQ has been reported to incite proliferation of mature hippocampal neural stem/progenitor cells via signaling pathways including GSK3β/p38-MAPK/β-catenin (Zhang et al., 2011). Moreover, it has been shown that physical exercise triggers hippocampal neurogenesis, facilitated by AdipoQ (Yaua et al., 2014). Furthermore, AdipoQ was found to be neurotrophic for spinogenesis and dendritic arborization in the DG in mice.
brains (Zhang et al., 2016). Several neuropathological characteristics, e.g., compromised motor activity and protein accumulation were improved by AdipoQ treatment in mouse experiments of α-synucleinopathies (Sekiyama et al., 2014). It was previously demonstrated that elderly AdipoQ-defective mice initiated an AD-like pathology linked with dysregulation of insulin receptor signaling (Ng et al., 2016).

The outcome of a cohort study performed by the Mayo Clinic Study of Aging indicated that elevated levels of plasma AdipoQ were interrelated with imaging data for cortical and hippocampal volumes, cognitive declines, and positron emission tomography (Wennberg et al., 2016). Therefore, the obtained results advocate that higher AdipoQ predicts cognitive decline and neurodegeneration in aging (Wennberg et al., 2016). Amazingly, these experimental outcomes were significant in females but not in males, which is consistent with the analyses of the Framingham Heart Study (van Himbergen et al., 2012). Consistent with the prediction that AdipoQ might be included in neurodegenerative pathogenesis, histopathological studies of an autopsy of an AD brain demonstrated that AdipoQ was segregated into the neurofibrillary tangles by tau (Waragai et al., 2016). AdipoQ also co-localized with Lewy bodies in the brain of dementia patients (Sekiyama et al., 2014). Along with plasma data regarding AdipoQ, the overexpression of AdipoQ might be associated with the progression of neurodegenerative disorders like AD. In a retrospective cohort study, Qizilbash et al. (2015) examined the involvement of BMI in developing dementia. Both underweight middle-aged and elderly people displayed an elevated probability of developing dementia within the next two decades. The presence of dementia started to decline with an increase in BMI, with highly obese patients (BMI >40 kg/m²) developing a 29% reduction (95% CI: 22-36) in the possibility of developing dementia than those of healthy-weight individuals.

Until now, the mode of hyperadiponectinemia in AD has not been clear. Hyperadiponectinemia in AD is expected to be a compensatory response to the lower efficiency of the insulin/insulin-like growth factor 1 (IGF-1) receptor signaling cascade during neurodegeneration (Waragai et al., 2017). As the disease progresses, AdipoQ might be increased as well as sequestered by tau, which ultimately leads to the aggregation of neurotoxic proteins in the AD brain (Figure 2; Waragai et al., 2016, 2017). A different alternative mechanism is that the misfolding of AdipoQ might downregulate the insulin/AdipoQ signal transduction network causing the reduction of neuroprotective and neurotrophic functions (Waragai et al., 2017). Therefore, it is expected that a mutation of AdipoQ may trigger synaptic dysfunction and neuronal death in AD.

CONCLUSION

Obesity in middle-aged people might be considered as a critical factor in the development and progression of AD in the elderly. The higher possibility of people with obesity to develop AD reveals the ability of adipose tissue to connect with the brain and influence its activity. AdipoQ signaling has been found to interact with a variety of neuropathological incidents such as Aβ formation and deposition, tau hyperphosphorylation, neuroinflammation, insulin resistance, cognitive damage, and synaptic loss. The phenotypes of AdipoQ or AdipoQ receptor-knockout mice recapitulates most of the AD neuropathological features. Thus, abnormal AdipoQ signaling may induce obesity-mediated harmful effects on the CNS and increase the risk of cognitive impairment and AD. Notably, in the brain, restoring typical AdipoQ signaling might establish constructive, disease-modifying therapeutics to combat AD.

AUTHOR CONTRIBUTIONS

MU conceived the original, designed the outlines of the study, and prepared the figures for the manuscript. MU, MR, and MS wrote the draft of the manuscript. PJ edited the whole manuscript. MSA, GA, MB-J, SM, MA-D, MFA, and AS revised and improved the draft. All authors have read and approved the final manuscript.

ACKNOWLEDGMENTS

This work was funded by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University, through the Fast-Track Research Funding Program. This work was supported by King Saud University, Deanship of Scientific Research, College of Science Research Center.

REFERENCES

Ali, T., Yoon, G. H., Shah, S. A., Lee, H. Y., and Kim, M. O. (2015). Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus. Sci. Rep. 5:11708. doi: 10.1038/srep11708

Arendt, T., Bigl, V., and Arendt, A. T. A. (1983). Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease. Acta Neuropathol. 61, 101–108.

Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyaizawa, I., et al. (2012). Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem. Biophys. Res. Commun. 425, 560–564. doi: 10.1016/j.bbrc.2012.08.024

Arshad, N. A., Lin, T. S., and Yahaya, M. F. (2018). Metabolic syndrome and its effect on the brain: possible mechanism. CNS Neurol. Disord. Drug Targets 17, 595–603. doi: 10.2174/1871527317666180724 143258

Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., and Landreth, G. E. (2003). A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation. J. Neurosci. 23, 2665–2674. doi: 10.1523/JNEUROSCI.23-07-02665.2003

Batista, A. F., Forny-Germano, L., Clarke, J. R., Lyra e Silva, N. M., Brito-Moreira, J., Brandke, S. E., et al. (2018). The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. J. Pathol. 245, 85–100. doi: 10.1002/path.5056
Beattie, E. C., Carroll, R. C., Yu, X., Morishita, W., Yasuda, H., von Zastrow, M., et al. (2000). Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat. Neurosci. 3, 1291–1300. doi: 10.1038/18123
Berg, A. H., Combs, T. P., and Scherer, P. E. (2002). ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 13, 84–89. doi: 10.1016/S1043-2760(01)00524-0
Bernstein, E. L., Koutka, P., Ljungquist, K., Breu, J., Canavan, B., and Grinspoon, S. (2004). Acute regulation of adiponectin by free fatty acids. Metabolism 53, 790–793. doi: 10.1016/j.metabol.2003.12.023
Bloemer, J., Pinky, P. D., Govindarajulu, M., Hong, H., Judd, R., Amin, R. H., et al. (2018). Role of AdipoQ in central nervous system disorders. Neural Plast. 2018:4593530. doi: 10.1155/2018/4593530
Bomfim, T. R., Forny-Germanno, L., Sathler, L. R., Boro-Moreira, J., Houzel, J. C., Decker, H., et al. (2012). An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Aβ oligomers. J. Clin. Invest. 122, 1339–1353. doi: 10.1172/JCI75256
Businaro, R., Ippoliti, E., Ricci, S., Canitano, N., and Fuso, A. (2012). Alzheimer’s disease’s promotion by obesity: induced mechanisms-molecular links and perspectives. Curr. Gerontol. Geriatr. Res. 2012:986823. doi: 10.1155/2012/986823
Capurso, C., and Capurso, A. (2012). From excess adiposity to insulin resistance: the role of free fatty acids. Vasc. Pharmacol. 57, 91–97. doi: 10.1016/j.vph.2012.05.003
Cezaretto, A., Suemoto, C. K., Bensendor, I., Lotufo, P. A., De Almeida-Pititto, B., and Almawi, W. Y. (2018). From excess adiposity to insulin resistance: basic science into clinical applications. Frontiers in Physiology.
AdipoQ in Obesity-Related Alzheimer’s Dementia

Uddin et al.

Polito, R., Nigro, E., Messina, A., Monaco, M. L., Monda, V., Scudiero, O., et al. (2018). Adiponectin and orexin-a as a potential immunity link between adipose tissue and central nervous system. *Front. Physiol.* 9:982. doi: 10.3389/fphys.2018.00982

Polito, R., Nigro, E., Pecoraro, A., Monaco, M. L., Perna, F., Sanduzzi, A., et al. (2019). Adiponectin receptors and pro-inflammatory cytokines are modulated in common variable immunodeficiency patients: correlation with Ig replacement therapy. *Front. Immunol.* 10:2812. doi: 10.3389/fimmu.2019.02812

Pousti, F., Ahmadi, R., Mirahmadi, F., Hosseinmardi, N., and Rohampour, K. (2018). Adiponectin modulates synaptic plasticity in hippocampal dentate gyrus. *Neurosci. Lett.* 662, 227–232. doi: 10.1016/j.neulet.2017.10.042

Polito, R. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., et al. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? *J. Alzheimers Dis.* 7, 63–80. doi: 10.3233/JAD-2005-7107

Stefan, N., and Stumvoll, M. (2002). Adiponectin-its role in metabolism and beyond. *Horm. Metab. Res.* 34, 469–474. doi: 10.1055/s-2002-34785

Sun, F., Lei, Y., You, J., Li, C., Sun, L., Garza, J., et al. (2019). Adiponectin modulates ventugal temporal area dopamine neuron activity and anxiety-related behavior through AdipoR1. *Mol. Psychiatry* 24, 124–144. doi: 10.1038/s41380-018-0109-2

Shah, S. A., Yoon, G. H., Chung, S. S., Abid, M. N., Kim, T. H., Lee, H. Y., Song, W., Huo, T., Guo, F., Wang, H., Wei, H., Yang, Q., et al. (2013). Globular adiponectin elicits neuroprotection by inhibiting NADPH oxidase-mediated oxidative damage in ischemic stroke. *Neuroscience* 248, 136–144. doi: 10.1016/j.neuroscience.2013.05.063

Spranger, J., Verma, S., Gühring, I., Bobbert, T., Seifert, J., Sindler, A. L., et al. (2006). Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. *Diabetes* 55, 141–147. doi: 10.2377/diabetes.a2005.06.d055-1077

Stein, E., Terry, R. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., et al. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? *J. Alzheimers Dis.* 7, 63–80. doi: 10.3233/JAD-2005-7107

Stefan, N., and Stumvoll, M. (2002). Adiponectin-its role in metabolism and beyond. *Horm. Metab. Res.* 34, 469–474. doi: 10.1055/s-2002-34785

Sun, F., Lei, Y., You, J., Li, C., Sun, L., Garza, J., et al. (2019). Adiponectin modulates ventugal temporal area dopamine neuron activity and anxiety-related behavior through AdipoR1. *Mol. Psychiatry* 24, 124–144. doi: 10.1038/s41380-018-0109-2

Takemura, Y., Ouchi, N., Shibata, R., Aprahamian, T., Kirber, M. T., Summer, R. S., et al. (2007). Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apototic bodies. *J. Clin. Invest.* 117, 375–386. doi: 10.1172/JCI29709

Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., et al. (2012). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. *J. Clin. Invest.* 122, 1316–1338. doi: 10.1172/JCI59903

Teixeira, A. V., Diniz, B. S., Campos, A. C., Miranda, A. S., Rocha, N. P., Talib, L. I., et al. (2013). Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer’s disease. *NeuroMolecular Med.* 15, 115–121. doi: 10.1007/s12017-012-8201-2

Terry, R. D., Masihah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., et al. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synaptic loss is the major correlate of cognitive impairment. *Ann. Neurol.* 30, 572–580. doi: 10.1002/ana.410300410

Thundyil, J., Pavlovski, D., Sobey, C. G., and Arumugam, T. V. (2012). Adiponectin receptor signalling in the brain. *Br. J. Pharmacol.* 165, 313–327. doi: 10.1111/j.1476-5381.2011.01560.x

Thundyil, J., Tang, S. C., Okun, E., Shah, K., Karamyan, V. T., and Li, Y. L., et al. (2010). Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death. *Exp. Transl Stroke Med.* 2:15. doi: 10.1186/2040-7378-2-15

Tsuchida, A., Yamauchi, T., Takekawa, S., Hada, Y., Ito, Y., Maki, T., et al. (2005). Peroxysome proliferator-activated receptor (PPAR) activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARα, PPARγ, and their combination. *Diabetes* 54, 3358–3370. doi: 10.2337/diabetes.a2005-3358

Uddin, M. S., and Kabir, M. T. (2019). “Oxidative stress in Alzheimer’s disease: molecular hallmarks of brain endothelial vulnerability” in Biological, diagnostic and therapeutic advances in Alzheimer’s disease. eds. G. M. Ashraf and A. Athanasios (Singapore: Springer), 91–115.

Uddin, M. S., Kabir, M. T., Al Mamun A., Barreto, G. E., Rashid, M., Pusaha, S., et al. (2020b). Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease. *Int. Immunopharmacol.* 84:106479. doi: 10.1016/j.intimp.2020.106479

Uddin, M. S., Kabir, M. T., Jeandon, P., Mathew, B., Ashraf, G. E., Pusaha, S., et al. (2020a). Novel anti-Alzheimer’s therapeutic molecules targeting amyloid precursor protein processing. *Oxidative Med. Cell. Longev.* 2020, 1–19. doi: 10.1155/2020/7039138

Uddin, M. S., Rahman, M. M., Jakaria, M., Rahman, M. S., Hossain, M. S., Islam, A., et al. (2020c). Estrogen signaling in Alzheimer’s disease: molecular insights and therapeutic targets for Alzheimer’s dementia. *Mol. Neurobiol.* 57, 2654–2670. doi: 10.1007/s12035-020-01911-8

Uddin, M. S., Tewari, D., Sharma, G., Kabir, M. T., Barreto, G. E., Bin-Jumah, M. N., et al. (2020d). Molecular mechanisms of ER stress and UPR in the pathogenesis of Alzheimer’s disease. *Mol. Neurobiol.* 57, 2902–2919. doi: 10.1007/s12035-020-01929-y

Ueda, K., Takeshi, Y., Abe, N., Nishida, T., Ohtera, F., Furukawa, K., et al. (2011). Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer’s disease. *Eur. J. Neuro. Sci.* 18, 1006–1009. doi: 10.1111/j.1468-1331.2010.03194.x

van Himmelberg, T. M., Beiser, A. S., AI, M., Seshadri, S., Otokozawa, S., Au, R., et al. (2012). Biomarkers for insulin resistance and inflammation and the
Waki, H., Yamauchi, T., Kamon, J., Ito, Y., Uchida, S., Kita, S., et al. (2003). Adiponectin induces a pro-inflammatory response in human astrocytic cells. Biochem. Biophys. Res. Commun. 304, 725–731.

Várhelyi, Z. P., Kálmán, J., Oláh, Z., Itricz, E. V., Fodor, E. K., Sáth ali, M., et al. (2017). Adiponectin receptors are less sensitive to stress in a transgenic mouse model of Alzheimer’s disease. Front. Neurosci. 11:199. doi: 10.3389/fnins.2017.00199

Venkatesh, B., Hickman, I., Nisbet, J., Cohen, J., and Prins, J. (2009). Changes in serum adiponectin concentrations in critical illness: a preliminary investigation. Crit. Care 13:R105. doi: 10.1186/cc7941

Vieira, M. N. N., and Beckman, D. (2017). Training microglia to resist Alzheimer’s disease. J. Biol. Chem. 282, 40352–40363. doi: 10.1074/jbc.M116.762582

Vieira, W. L., Atti, A. R., Gatz, M., Pedersen, N. L., and Johansson, B. F. L. (2016). Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288–1295. doi: 10.1038/nm778

Yamauchi, T., Kamon, J., Yano, K., Uchida, S., et al. (2002). Soluble oligomers of β amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133–140. doi: 10.1016/S0006-8993(01)03058-X

Wang, S., Zhou, Y., Bo, Y., Li, L., Yu, S., Chen, Y., et al. (2016). C1q/tumor necrosis factor-related protein-3 attenuates brain injury after intracerebral hemorrhage via AMPK-dependent pathway in rat. Front. Cell. Neurosci. 10:237. doi: 10.3389/fncel.2016.00237

Waragai, M., Adame, A., Tinth, L., Sekiyama, K., Takamatsu, Y., Une, K., et al. (2016). Possible involvement of adiponectin, the anti-diabetes molecule, in the pathogenesis of Alzheimer’s disease. J. Alzheimers Dis. 52, 1453–1459. doi: 10.3237/JAD-15-11116

Waragai, M., Ho, G., Takamatsu, Y., Sekiyama, K., Sugama, S., and Takenouchi, T., et al. (2017). Importance of adiponectin activity in the pathogenesis of Alzheimer’s disease. Ann. Clin. Transl. Neuro. 4, 591–600. doi: 10.1002/acn3.436

Wennergren, A. M. V., Gustafson, D., Hagen, C. E., Roberts, R. O., Knopman, D., Jack, C., et al. (2016). Serum Adiponectin levels, neuroimaging, and cognition in the Mayo Clinic study of aging. J. Alzheimers Dis. 53, 573–581. doi: 10.3233/JAD-151201

Whitehead, J. P., Richards, A. A., Hickman, I. J., Macdonald, G. A., and Prins, J. B. (2006). Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes. Metab. 8, 264–280. doi: 10.1111/j.1463-1326.2005.00510.x

Whitmer, R. A., Gunderson, E. P., Barrett-Connor, E., Quesenberry, C. P., and Whitehead, J. P., Richards, A. A., Hickman, I. J., Macdonald, G. A., and Ur, E. (2007). Adipokine gene expression in brain tissue of a mouse model of Alzheimer’s disease. J. Neurotrauma 24, 264–280. doi: 10.1089/jn.2006.16.19

Xu, W. L., Atti, A. R., Gatz, M., Pedersen, N. L., and Johansson, B. F. L. (2016). Possible involvement of adiponectin, the anti-diabetes molecule, in the pathogenesis of Alzheimer’s disease. Mol. Neurodegeneration 11:4. doi: 10.1186/s13288-016-0192-0

Yang, B., Wang, S., Yu, S., Chen, Y., Li, L., Zhang, H., et al. (2017). C1q/tumor necrosis factor-related protein 3 inhibits oxidative stress during intracerebral hemorrhage via PKA signaling. Brain Res. 1657, 176–184. doi: 10.1016/j.brainsci.2016.11.014

Yarchoan, M., and Arnold, S. E. (2014). Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63, 2253–2261. doi: 10.2337/db14-0287

Yaua, S. Y., Lai, A., Hoo, R. L. C., Ching, Y. P., Christied, B. R., Leea, T. M. C., et al. (2014). Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin. Proc. Natl. Acad. Sci. U. S. A. 111, 15810–15815. doi: 10.1073/pnas.1415219111

Yoon, G., Shah, S. A., Ali, T., and Kim, M. O. (2018). The Adiponectin homolog osmotin enhances neurite outgrowth and synaptic complexity via AdipoR1/NGR1 signaling in Alzheimer’s disease. Mol. Neurobiol. 55, 6673–6686. doi: 10.1007/s12035-017-0847-1

Yu, J. G., Javorschi, S., Hevener, A. L., Kruzyszynka, Y. T., Norman, R. A., and Sinha, M., et al. (2002). The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51, 2968–2974. doi: 10.2337/diabetes.51.10.2968

Zhang, D., Guo, M., Zhang, W., and Lu, X. Y. (2011). Adiponectin stimulates proliferation of adult hippocampal neural stem/progenitor cells through activation of p38 mitogen-activated protein kinase (p38MAPK)/glycogen synthase kinase 3β (GSK-3β)/β-catenin signaling cascade. J. Biol. Chem. 286, 44913–44920. doi: 10.1074/jbc.M111.310052

Zhang, D., Wang, X., and Lu, X. Y. (2016). Adiponectin exerts neurotrophic effects on dendritic arborization, spinogenesis, and neurogenesis of the dentate gyrus of male mice. Endocrinology 157, 2853–2869. doi: 10.1210/en.2015-2078

Zhang, D., Wang, X., Wang, B., Garza, J. C., Fang, X., Wang, J., et al. (2017). Adiponectin regulates contextual fear extinction and intrinsic excitability of dentate gyrus granule neurons through AdipoR2 receptors. Mol. Psychiatry 22, 1044–1055. doi: 10.1038/mp.2016.38

Zhao, W. Q., Chen, H., Quon, M. J., and Alkon, D. L. (2004). Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 490, 71–81. doi: 10.1016/j.ejphar.2004.02.045

Zhao, L., Chen, S., Sherchan, P., Ding, Y., Zhao, W., Guo, Z., et al. (2018). Recombinant CTRP9 administration attenuates neuroinflammation via activating adiponectin receptor 1 after intracerebral hemorrhage in mice. J. Neuroinflammation 15:215. doi: 10.1186/s12974-018-1256-8

Zhou, Q., Xiang, H., Li, A., Lin, W., Huang, Z., Guo, J., et al. (2019). Activating Adiponectin signaling with exogenous Adiponutin reduces myelin lipid accumulation and suppresses macrophage recruitment after spinal cord injury. J. Neurotrauma 36, 903–918. doi: 10.1089/neu.2018.5783

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.